Kumaraswamy Naidu Chitrala
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 5 | 2024 | 324 | 1.720 |
Why?
|
| Breast Neoplasms | 6 | 2025 | 1679 | 1.420 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2025 | 858 | 1.270 |
Why?
|
| Genome-Wide Association Study | 9 | 2025 | 421 | 1.050 |
Why?
|
| Models, Molecular | 4 | 2019 | 875 | 0.950 |
Why?
|
| Estrogen Receptor alpha | 2 | 2019 | 120 | 0.930 |
Why?
|
| Carrier Proteins | 3 | 2019 | 318 | 0.930 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 233 | 0.880 |
Why?
|
| Ligands | 4 | 2019 | 387 | 0.850 |
Why?
|
| Frontotemporal Dementia | 1 | 2023 | 5 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 150 | 0.790 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2021 | 547 | 0.740 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 211 | 0.710 |
Why?
|
| Gene Regulatory Networks | 3 | 2024 | 143 | 0.700 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2021 | 18 | 0.690 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2024 | 933 | 0.630 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 21 | 0.610 |
Why?
|
| DNA Methylation | 2 | 2019 | 393 | 0.600 |
Why?
|
| Phenotype | 5 | 2022 | 774 | 0.600 |
Why?
|
| Molecular Dynamics Simulation | 5 | 2019 | 183 | 0.590 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 971 | 0.590 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2018 | 49 | 0.570 |
Why?
|
| Interleukin-15 | 1 | 2016 | 13 | 0.520 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2017 | 55 | 0.510 |
Why?
|
| Databases, Genetic | 1 | 2016 | 103 | 0.490 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 246 | 0.460 |
Why?
|
| Benzofurans | 1 | 2014 | 22 | 0.440 |
Why?
|
| Humans | 27 | 2025 | 42113 | 0.430 |
Why?
|
| Carcinogens | 1 | 2014 | 126 | 0.420 |
Why?
|
| BRCA1 Protein | 2 | 2025 | 58 | 0.410 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 122 | 0.400 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 72 | 0.400 |
Why?
|
| Leukemia | 2 | 2023 | 54 | 0.390 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 93 | 0.380 |
Why?
|
| Computer Simulation | 1 | 2014 | 404 | 0.370 |
Why?
|
| Proteins | 1 | 2014 | 383 | 0.360 |
Why?
|
| Binding Sites | 3 | 2019 | 670 | 0.360 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1066 | 0.350 |
Why?
|
| Melanoma | 2 | 2022 | 109 | 0.350 |
Why?
|
| Software | 1 | 2013 | 234 | 0.340 |
Why?
|
| Protein Binding | 3 | 2019 | 1076 | 0.320 |
Why?
|
| Membrane Proteins | 1 | 2013 | 548 | 0.320 |
Why?
|
| Mice | 8 | 2023 | 6490 | 0.300 |
Why?
|
| Female | 12 | 2025 | 23980 | 0.290 |
Why?
|
| Lipids | 3 | 2025 | 256 | 0.290 |
Why?
|
| Molecular Conformation | 2 | 2019 | 157 | 0.250 |
Why?
|
| Protein Structure, Tertiary | 2 | 2018 | 427 | 0.230 |
Why?
|
| Protein Conformation | 2 | 2019 | 420 | 0.230 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 979 | 0.220 |
Why?
|
| Molecular Structure | 2 | 2019 | 560 | 0.210 |
Why?
|
| Aging | 2 | 2019 | 763 | 0.210 |
Why?
|
| Animals | 8 | 2023 | 16694 | 0.200 |
Why?
|
| Alleles | 2 | 2021 | 351 | 0.200 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 683 | 0.200 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 274 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 290 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 727 | 0.180 |
Why?
|
| Genotype | 2 | 2022 | 792 | 0.180 |
Why?
|
| Calcium Signaling | 1 | 2022 | 108 | 0.180 |
Why?
|
| Urban Population | 2 | 2025 | 364 | 0.180 |
Why?
|
| Interferon-gamma | 1 | 2022 | 268 | 0.180 |
Why?
|
| Apolipoprotein E4 | 1 | 2022 | 62 | 0.180 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2021 | 27 | 0.170 |
Why?
|
| DNA Damage | 1 | 2023 | 358 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 406 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2022 | 137 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2020 | 88 | 0.160 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2019 | 5 | 0.160 |
Why?
|
| Metalloendopeptidases | 1 | 2019 | 15 | 0.160 |
Why?
|
| Glutathione Transferase | 1 | 2019 | 90 | 0.150 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2019 | 41 | 0.150 |
Why?
|
| Middle Aged | 7 | 2025 | 11790 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2021 | 386 | 0.150 |
Why?
|
| Mutation | 2 | 2025 | 1169 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 201 | 0.140 |
Why?
|
| Mice, Knockout | 2 | 2022 | 1010 | 0.140 |
Why?
|
| Carbazoles | 1 | 2018 | 46 | 0.140 |
Why?
|
| Amino Acids | 1 | 2019 | 150 | 0.140 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2019 | 110 | 0.140 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 491 | 0.140 |
Why?
|
| Cholesterol | 2 | 2022 | 230 | 0.130 |
Why?
|
| Fatty Acids, Volatile | 1 | 2017 | 8 | 0.130 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2017 | 40 | 0.130 |
Why?
|
| Propionates | 1 | 2017 | 27 | 0.130 |
Why?
|
| Bacteroidetes | 1 | 2017 | 13 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2019 | 205 | 0.130 |
Why?
|
| Indoles | 1 | 2018 | 178 | 0.130 |
Why?
|
| Metagenomics | 1 | 2017 | 43 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2019 | 267 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2017 | 168 | 0.130 |
Why?
|
| Feces | 1 | 2017 | 126 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 190 | 0.120 |
Why?
|
| Adult | 6 | 2025 | 13437 | 0.120 |
Why?
|
| Phosphorylation | 1 | 2019 | 973 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1058 | 0.120 |
Why?
|
| Dioxins | 1 | 2014 | 8 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 728 | 0.110 |
Why?
|
| Male | 7 | 2025 | 22745 | 0.110 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 87 | 0.110 |
Why?
|
| Hypertension | 1 | 2021 | 817 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 165 | 0.100 |
Why?
|
| Genetic Loci | 2 | 2025 | 102 | 0.100 |
Why?
|
| Depression | 1 | 2019 | 837 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 1804 | 0.090 |
Why?
|
| Multifactorial Inheritance | 2 | 2021 | 32 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1554 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 1129 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2025 | 1728 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 2598 | 0.060 |
Why?
|
| Phthalazines | 1 | 2025 | 4 | 0.060 |
Why?
|
| Rad51 Recombinase | 1 | 2025 | 7 | 0.060 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2025 | 40 | 0.060 |
Why?
|
| Piperazines | 1 | 2025 | 117 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 6 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2023 | 8 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2023 | 6 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 15 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2023 | 50 | 0.050 |
Why?
|
| Aged | 3 | 2019 | 7958 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2022 | 74 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 437 | 0.050 |
Why?
|
| Epithelium | 1 | 2022 | 78 | 0.050 |
Why?
|
| Methylation | 1 | 2022 | 118 | 0.050 |
Why?
|
| Esophagus | 1 | 2022 | 44 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2021 | 85 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 2021 | 12 | 0.040 |
Why?
|
| Population Groups | 1 | 2021 | 59 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 3073 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 179 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2022 | 281 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 88 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 242 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2022 | 253 | 0.040 |
Why?
|
| Genetics | 1 | 2020 | 10 | 0.040 |
Why?
|
| Genome, Human | 1 | 2021 | 143 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 289 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 594 | 0.040 |
Why?
|
| Glucosylceramidase | 1 | 2019 | 6 | 0.040 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2019 | 13 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 487 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 179 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 107 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 122 | 0.040 |
Why?
|
| Cell Line | 1 | 2022 | 1416 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 426 | 0.040 |
Why?
|
| Cognition | 1 | 2022 | 458 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2021 | 658 | 0.030 |
Why?
|
| Longevity | 1 | 2019 | 167 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 660 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 844 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2017 | 180 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1019 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 1221 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 1570 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 640 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 661 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2022 | 2111 | 0.030 |
Why?
|
| Macrophages | 1 | 2017 | 515 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2790 | 0.020 |
Why?
|
| Inflammation | 1 | 2017 | 729 | 0.020 |
Why?
|